Skadden represented Watson Pharmaceuticals, Inc. in securing antitrust approvals by the U.S. Federal Trade Commission (on October 15) and the European Commission (on October 5) of its $5.6 billion acquisition of Actavis Group, announced earlier this year.

BACK TO TOP